Novogen is a rapidly expanding international biotechnology company based in Australia and the USA.


Novogen has three key aims:



  1. To maintain its position as the world leader in the area of isoflavonoid drug technology;

  2. To convert the Novogen technology platform into products that will successfully treat and prevent the major degenerative diseases of humans;

  3. To establish a business model and investment opportunity that will return increasing value to shareholders.


 








Marshall Edwards completes rights offering to stockholders
14 May 2012

MARSHALL EDWARDS COMPLETES RIGHTS OFFERING TO ...More



Novogen Board approves US$4m investement in Marshall Edwards rights offering
8 May 2012
Novogen Limited (ASX: NRT Nasdaq: NVGN), announced today that ...More



Marshall Edwards issued new patent for use of ME-143 in treating cancer
26 April 2012
Novogen Limited’s subsidiary, Marshall Edwards, Inc., (NASDAQ: ...More






Chairman's address at Novogen EGM
Friday, 6 May 2011

Novogen Extraordinary Meeting

Chairman’s Address

6 May, 2011

Welcome to the Novogen Extraordinary
...More
 


About Novogen | Knowledge Base | Pharmaceuticals | News | Investor Relations | Contact | Site Map
Copyright © 2012 Novogen The world leader in isoflavone research - with products including Promensil and Trinovin | Web Design by Newgency